Concomitant drug use of nirmatrelvir/ritonavir and CYP3A4-modulating antimicrobial agents : an approach for drug use
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
European journal of hospital pharmacy : science and practice - 31(2024), 2 vom: 22. Feb., Seite 180-182 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Visscher, Robbert [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.02.2024 Date Revised 28.02.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/ejhpharm-2023-003795 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356092879 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356092879 | ||
| 003 | DE-627 | ||
| 005 | 20240229170113.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/ejhpharm-2023-003795 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1310.xml |
| 035 | |a (DE-627)NLM356092879 | ||
| 035 | |a (NLM)37105711 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Visscher, Robbert |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Concomitant drug use of nirmatrelvir/ritonavir and CYP3A4-modulating antimicrobial agents |b an approach for drug use |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.02.2024 | ||
| 500 | |a Date Revised 28.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a CLINICAL MEDICINE | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a MICROBIOLOGY | |
| 650 | 4 | |a Pharmacology | |
| 650 | 4 | |a Safety | |
| 650 | 7 | |a nirmatrelvir |2 NLM | |
| 650 | 7 | |a 7R9A5P7H32 |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 650 | 7 | |a Cytochrome P-450 CYP3A |2 NLM | |
| 650 | 7 | |a EC 1.14.14.1 |2 NLM | |
| 650 | 7 | |a Anti-Infective Agents |2 NLM | |
| 650 | 7 | |a Lactams |2 NLM | |
| 650 | 7 | |a Leucine |2 NLM | |
| 650 | 7 | |a GMW67QNF9C |2 NLM | |
| 650 | 7 | |a Nitriles |2 NLM | |
| 650 | 7 | |a Proline |2 NLM | |
| 650 | 7 | |a 9DLQ4CIU6V |2 NLM | |
| 700 | 1 | |a Yalçın, Nadir |e verfasserin |4 aut | |
| 700 | 1 | |a Bayraktar, Izgi |e verfasserin |4 aut | |
| 700 | 1 | |a Bayraktar-Ekincioglu, Aygin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of hospital pharmacy : science and practice |d 2012 |g 31(2024), 2 vom: 22. Feb., Seite 180-182 |w (DE-627)NLM225772213 |x 2047-9956 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2024 |g number:2 |g day:22 |g month:02 |g pages:180-182 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/ejhpharm-2023-003795 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2024 |e 2 |b 22 |c 02 |h 180-182 | ||